About Dana Fowlkes
This author has not written his bio yet.
But we are proud to say that Dana Fowlkes contributed 54 entries already.
Entries by Dana Fowlkes
Lillian Chiang, CEO, presents at BioCentury Conference
Lillian Chiang, Evrys Bio’s CEO, presents at BioCentury’s East-West Biopharma Summit October 2-4 in Boston https://conferences.biocentury.com/east-west-summit
Lou Kassa, CEO of the Hepatitis B Foundation, Blumberg Institute & Pennsylvania Biotechnology Center (PABC), talks with Dr. Lillian Chiang, CEO of Evrys Bio
Listen Here: https://www.buzzsprout.com/2098231/13449574
The Beginninng of the End of the Pandemic Era
The global scientific and technical response to the Covid-19 pandemic illustrates the power of 21st century medical science and technology. Clearly, a goal, based upon that we’ve learned, can be and should be the elimination of future pandemics. While Evrys Bio’s daily work is on the development of therapeutics for a broad range of viral […]
Advancing new tools for infectious diseases: Therapeutics and vaccine development for infectious diseases could be transformed
Therapeutics and vaccine development for infectious diseases could be transformed according to Viewpoint published in Science this week by Rajesh Gupta (SCIENCE20 NOV 2020 : 913-914)* Please read the whole article for a look a modern approach to infectious diseases here: SCIENCE 20 NOV 2020
Main Menu
- Home
- Our Team
- Platform & Pipeline
- Platform and Pipeline
- An-allosteric-inhibitor-of-sirtuin-2-blocks-hepatitis-B-virus
- Drugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity
- An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity
- Evrys SIRT2 Modulator Promotes Death of HCMV-Infected Monocytes, August 2023”.
- Evrys SIRT2 Allosteric Modulator with Broad-Spectrum Antiviral Activity, June 2023”.
- Curated Publications about Sirtuins
- News
- Contact Us
- Evrys Bio Slide Deck
- Jobs
Evrys Bio
3805 Old Easton Road
Doylestown, PA 18902
Federal Conflict of Interest Policy Statement
